Avenue Therapeutics, Inc.
ATXI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $10 | $3 | $1 |
| G&A Expenses | $5 | $4 | $5 | $2 |
| SG&A Expenses | $5 | $4 | $5 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $15 | $8 | $4 |
| Operating Income | -$11 | -$15 | -$8 | -$4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $4 | $4 | $0 |
| Pre-Tax Income | -$12 | -$10 | -$4 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$10 | -$4 | -$4 |
| % Margin | – | – | – | – |
| EPS | -0.9 | -73.6 | -121.91 | -3.29 |
| % Growth | 98.8% | 39.6% | -3,605.5% | – |
| EPS Diluted | -0.9 | -73.48 | -121.91 | -3.29 |
| Weighted Avg Shares Out | 13 | 0 | 0 | 1 |
| Weighted Avg Shares Out Dil | 13 | 0 | 0 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $15 | $0 | $4 |
| EBITDA | -$12 | $4 | -$2 | $0 |
| % Margin | – | – | – | – |